Oscient Pharmaceuticals Corp. (OSCI) | Stock Discussion Forums

web analytics

Advertise on SI

web analytics

Biotech / Medical | Oscient Pharmaceuticals Corp. (OSCI)

Previous 10 | Next 10

To: Peter Shaw who wrote (319)	11/22/1997 3:34:00 PM
From: joemjo	of 1154

This may be a little dated but it does show the expansion of the commitment to the genomic field of the big players. Bristol-Myers Squibb Appoints Applied Genomics Leader; Elliott Sigal to Head New Department Exploring Genetic Links to Disease PR Newswire - November 17, 1997 09:45 BMY AFFX MNLM INCY GENE %MTC %PER %CON %JVT V%PRN P%PRN Jump to first matched term PRINCETON, N.J., Nov. 17 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced the appointment of Elliott Sigal, M.D., Ph.D., to the newly created position of vice president, Applied Genomics, Drug Discovery. Dr. Sigal will lead the Company's new Department of Applied Genomics established to apply the rapid advancements in genomic information and disease genetics to major drug discovery and development programs. Dr. Sigal reports directly to William H. Koster, Ph.D., senior vice president, Drug Discovery Research. In his new role, Dr. Sigal will be responsible for establishing the initial scientific and technical strategy of the Department of Applied Genomics. In conjunction with the company's existing therapeutic areas, Dr. Sigal will apply the use of genomics techniques to identify specific human disease targets and to assist in optimizing various drug discovery and development programs. Dr. Sigal brings strong industry and academic experience to his new position at Bristol-Myers Squibb. He joins the Company from the genomics firm, Progenitor of Menlo Park, Calif., where he was senior vice president, Research and Development. Before the merger of Progenitor with Mercator Genetics completed last August, he served as president, chief executive officer and research director of Mercator. Under his direction, Mercator scientists last year isolated the gene for the common iron overload disorder, hemochromatosis. Between 1992 and 1995, Dr. Sigal worked for Syntex, Inc., including positions as executive director of Cell Biology, and later vice president for Inflammation and Immunology Research for the Roche Bioscience organization. Since 1988, Dr. Sigal has held several faculty positions at the University of California, San Francisco (UCSF). "We're pleased and excited that Elliott Sigal will lead our new effort in applied genomics," Dr. Koster said. "He brings with him an impressive record of scientific and commercial achievements and he will provide the high-caliber leadership required to reach our goal of building a world-class genomics program. "Dr. Sigal's decision to join our organization is a critical step forward in the growth plans of Drug Discovery," Dr. Koster continued. "His expertise will allow us to take full advantage of technological advances that will be used to elucidate the relationship of genetic structure to disease, to identify new drug targets and to improve the methods used to develop new drugs for the clinic." The Department of Applied Genomics will be the focal point for the application of genomics technologies at Bristol-Myers Squibb to advance the business objectives and strategies for its Worldwide Pharmaceutical Group. Genomics will be utilized to discover new molecular targets for discovery programs by using informatics to "mine" both proprietary and non-proprietary databases available as well as the identification and functional characterization of novel genes. In addition to enhancing the drug discovery process at Bristol-Myers Squibb, the Department of Applied Genomics will be a driving force behind the application of advanced genomics capabilities to the company's drug development process. The Department will be instrumental in applying new genomic technologies to understand the role of genetic factors in determining the therapeutic response to drugs as well as in the modulation of metabolism and potential toxicities of new drug candidates. The Department of Applied Genomics will be headquartered at the company's new research and administrative campus in Hopewell Township, N.J. Hiring for the new positions is actively underway. In addition to coordinating Bristol-Myers Squibb's internal research efforts in genomics, Dr. Sigal will manage outside genomics collaborations with biotechnology firms and academic institutions. One of the company's largest collaborations of this kind is a unique consortium with Affymetrix Inc. (Nasdaq: AFFX) and Millennium Pharmaceuticals (Nasdaq: MNLM) to fund research at the Whitehead Institute/MIT Center for Genome Research. Projects funded by the consortium are directed by Eric S. Lander, Ph.D., a pioneer in genomics research. Other Company collaborations in genomics include Incyte Pharmaceuticals, Inc. (Nasdaq: INCY) and Genome Therapeutics Corp. (Nasdaq: GENE) which are both enhancing and expanding Bristol-Myers Squibb's access to genomics data. A multi-year agreement with Incyte gives Bristol-Myers Squibb access to Incyte's rapidly expanding human sequence and expression database, LifeSEQ(R), while the alliance with Genome Therapeutics provides access to its proprietary microbial sequence database, PathoGenome(TM). Dr. Sigal received his B.S., M.S. and Ph.D. degrees in Industrial Engineering from Purdue University and his M.D. degree from the University of Chicago. He is Board Certified in Internal Medicine and in Pulmonary Medicine. Post-doctoral research training in pulmonary molecular biology was received at UCSF. His positions at the UCSF have included Graduate Faculty, Molecular Medicine, Program in Biological Sciences; Associate Adjunct Professor of Medicine; and Associate Staff Member, Cardiovascular Research Institute. Bristol-Myers Squibb is a diversified worldwide health and personal care company whose principal businesses are pharmaceuticals, consumer products, nutritionals and medical devices. It has established research programs in the areas of cardiovascular, metabolic and infectious diseases, central nervous system and dermatological disorders, oncology, immunology and inflammation, and pain management. In June, the Company announced plans to expand its research and development operations to help meet its long-term growth and performance objectives. The expansion is expected to increase Bristol-Myers Squibb's research and development staff by about 2,000 people over the next five or so years. SOURCE Bristol-Myers Squibb Company /CONTACT: Peggy Ballman, 609-252-5323, or Sylvia Sharockman, 609-252-6540, both of Bristol-Myers Squibb/ /Company News On-Call: Bristol-Myers Squibb press releases available by fax, 800-758-5804, ext. BMYFAX, or 269329, or at prnewswire.com /Web site: http:/www.bms.com/ (BMY AFFX MNLM INCY GENE)

Share	Recommend \| Keep \| Reply \| Mark as Last Read

To: OldAIMGuy who wrote (321)	11/24/1997 10:31:00 AM
From: joemjo	of 1154

To All, Frost & Sullivan: DNA Microchips: Current Exploration of Niche Markets Will Produce Large Future Dividends PR Newswire - November 24, 1997 05:00 %MTC V%PRN P%PRN Jump to first matched term MOUNTAIN VIEW, Calif., Nov. 24 /PRNewswire/ -- There have been three revolutions in modern biology: the discovery of DNA, genetic engineering, and the utilization of genes to cure disease. DNA microchips are fueling this third revolution by providing an automated, high-throughput technology which allows scientists to map out genetic codes found in DNA, creating a potentially multi-billion dollar market in the biopharmaceutical industry. A Strategic Assessment of the DNA Microchip Market, strategic research by Frost & Sullivan (www.frost.com), examines the end-user applications of this exciting new technology including genomics, clinical diagnostics, and disease management. Currently, genomics, the understanding of the human genome for developing therapeutic products to treat disease, is the most financially successful application for DNA microchips. But with the introduction of the Affymetrix' GeneChip for HIV genotyping, it is obvious that applications for clinical diagnostics are not far behind. "DNA microchips are experiencing growth in genomics, not only because of the interest fueled by the human genome project, but by its ability to greatly accelerate drug discovery," said Enal Razvi Ph.D., Frost & Sullivan senior biotechnology analyst. "However in four to five years, once they receive the necessary FDA approval, the clinical diagnostics market will explode as doctors utilize these chips to test for a variety of life-threatening conditions at a much lesser cost than what's currently available on the market." For all its potential, long-term financing has become an issue in this emerging market as investments do not provide immediate financial rewards. The most secure way to receive financing has been through acquiring exclusive intellectual property and developing strategic partnerships. Thus far stock market valuations have been based more on patents and alliances than on the revenues companies generate. A Strategic Assessment of the DNA Microchip Market profiles many of the current market competitors and those anticipated to make a significant impact through 2001. Each competitor has been evaluated in terms of company history, competitive strategy, strengths, limitations, collaborations, as well as revenues where appropriate. Selected Participants in this market include Affymetrix, Orchid Biocomputer, Darwin Molecular Corporation, Sarnoff Corporation, Gene Logic, GeneTrace Systems, Genometrix, Hyseq, Incyte Pharmaceuticals, Molecular Tool, Mosaic Technologies, Nanogen, Perkin-Elmer Applied Biosystems Division, Pharmacia Biotech, Synteni, and Vysis. Related Companies in this market include Affymax Research Institute, Argonne National Laboratory, Aurora Biosciences Corporation, Beckman Instruments, Becton Dickinson, Caliper Technologies, Exelixis Pharmaceuticals, Genome Therapeutics Corp., Hewlett-Packard Company, Human Genome Sciences, MicroFab Technologies, Millennium Pharmaceuticals, PerSeptive Biosystems, Sequana Therapeutics, Third Wave Technologies, and Visible Genetics. This medical industry research has integrated the proven Frost & Sullivan Market Engineering consulting philosophy into the entire research process. Critical phases of this research included: identification of industry challenges, market engineering measurements, strategic recommendations, planning and market monitoring. All of the vital elements of this system help the market participants navigate successfully through the DNA microchip market. Frost & Sullivan is an international marketing consulting company that monitors the medical industry for market trends, market measurements, and strategies. The ongoing research is utilized to update a series of research publications such as #5066-53, U.S. DNA Probe Markets, and to support industry participants with customized consulting needs. Free executive summaries of all Frost & Sullivan reports are available to the press. For more information in the United States, contact: Keith Hammond California 650-237-4384 650-903-0915 fax khammond@frost.com Or, visit the company's web site: frost.com SOURCE Frost and Sullivan /CONTACT: Keith Hammond of Frost & Sullivan, 650-237-4384, or fax, 650-903-0915, or khammond@frost.com/ /Web site: frost.com

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (1)

To: joemjo who wrote (322)	12/4/1997 3:19:00 PM
From: joemjo	of 1154

Genome Therapeutics Announces Release of Version 2.0 of PathoGenome Database PR Newswire - December 04, 1997 11:59 GENE %MTC %CPR %PDT V%PRN P%PRN Jump to first matched term NEW YORK, Dec. 4 /PRNewswire/ -- Genome Therapeutics Corp. (Nasdaq: GENE) announced today, during a presentation at the 14th Annual BancAmerica Robertson Stephens Medical Conference, that it has released version 2.0 of the Company's proprietary microbial sequence database, PathoGenome(TM). Release 2.0 utilizes a more powerful and efficient bioinformatics platform and features highly-finished genomic sequence information for more than a dozen microbial pathogens, including Enterococcus faecium, Enterococcus faecalis, Streptococcus pneumoniae, and Staphylococcus epidermidis. PathoGenome(TM) Database Release 2.0 is being installed at the research facilities of current subscribers: Bayer AG, Bristol-Myers Squibb and Schering-Plough, and is now available to new subscribers. The PathoGenome(TM) Database, which is designed to facilitate the development of novel anti- infectives, was initially launched in May 1997. "High-quality sequencing and finishing of microbial genomes is critical to the drug development process. Without this level of detail, it becomes difficult or impossible to identify all of the genes of an organism and assign functions to essential genes," said Robert J. Hennessey, Chairman, President and CEO of Genome Therapeutics. "The high-quality finishing of pathogen genomes is an area of considerable expertise for Genome Therapeutics, perhaps best represented in the recent finishing of Staphylococcus epidermidis to less than 50 contigs (large sequence segments). Genome sequences typically available to pharmaceutical companies contain as many as 500 - 1,500 contigs, leaving many gaps, missing genes or interrupted information on key genes that could be potential drug targets." Mr. Hennessey added, "The feedback we've received from our customers has been excellent, with reports of new potential anti-infective targets already identified. This rapid success underscores the power of comparative genomics to define targets that are common to multiple organisms. We look forward to announcing additional subscribers, as well as expanding relationships with our current subscribers to include identification of essential genes within the microbial sequences and the functional characterization of those essential genes." The PathoGenome(TM) Database provides subscribers with an unprecedented volume of highly organized and functionally annotated sequence information related to some of the most medically important microbial organisms and fungi. The database is designed for use at the client site utilizing proprietary bioinformatics software developed at Genome Therapeutics, enabling researchers to search for new genes among multiple pathogens and cross-reference genomic information. Genome Therapeutics Corporation is a leader in the field of genomics -- the identification and functional characterization of genes. The Company's commercial gene discovery strategy is to identify and characterize human genes associated with major diseases and elucidate bacterial genes responsible for many serious infectious diseases. Together with its strategic partners, Genome Therapeutics is using genomic information to develop a new generation of pharmaceuticals. Statements in this press release that are not strictly historical are "forward looking" statements as defined in the Private Securities Litigation Reform Act of 1995. The actual results may differ from those projected in the forward looking statement due to risks and uncertainties that exist in Genome Therapeutics' operations and business environment, described more fully in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission. SOURCE Genome Therapeutics Corp. /CONTACT: Christopher Taylor, Director of Investor Relations of Genome Therapeutics Corp., 781-398-2466, or Douglas E. MacDougall of Feinstein Kean Partners, 617-577-8110/ /Web site: genomecorp.com (GENE)

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (2)

To: OldAIMGuy who wrote (325)	12/9/1997 7:25:00 PM
From: joemjo	of 1154

Tom, I am concerned about the drop. I held but sure don't like the price action and volume. Looking at the year high I realize most purchases this year are now at a lose. I am hoping this is the culmination of tax selling and not representative of a fundamental change in the company. I may add later in the month if I can hold onto my tax selling thesis. Do you compare GENE's price action with others in the same group? I guess I'll check INCY,SGNA,HGSI,MLNM,&MYGN. Any others you know of? I would rather have seen some buying after the Robert Stephens conference not selling, Oh well. Todd

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (2)

To: joemjo who wrote (326)	12/9/1997 7:48:00 PM
From: Machaon	of 1154

Biotechs have been, mostly, out of favor for a while now. I attribute some of the latest negative actions to tax loss selling, and expect it to continue for a while, until the selling is balanced out with opportunistic buying. I guess that traders have until the end of the month to sell some of their losers. To me, it makes great buying opportunities. "One man's poison is another man's pleasure" On Yahoo quotes you can type ^ixb where you normally enter a stock code, and get the biotech index "results" during each day. Today, the index was down 1.01%. Fidelity's biotech fund, which is usually more into larger biotechs and pharmaceudicals was down about 1.4%. You can get Fidelity's biotech quote, after 7pm each day to get the updated quote, by asking for a quote on FBIOX, instead of a stock code in the "stock quote" box. Regards, Bob

Share	Recommend \| Keep \| Reply \| Mark as Last Read \| Read Replies (1)

Previous 10 | Next 10

Copyright/IP Policy

Copyright © 1995-2013 Knight Sac Media. All rights reserved.